ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1497

Efficacy and Safety of Iguratimod for Rheumatoid Arthritis

Tsuneo Kondo1, Akiko Shibata1, Ryota Sakai1, Kentaro Chino1, Ayumi Okuyama1, Hirofumi Takei1 and Koichi Amano2, 1Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan, 2Saitama Medical Center, Saitama Medical University, Kawagoe, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: DMARDs, Janus kinase (JAK), New Therapeutics, rheumatoid arthritis (RA) and treatment options

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Novel therapies, Biosimilars, Strategies and Mechanisms in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Iguratimod is a new small-molecular drug for rheumatoid arthritis (RA), which was approved on June, 2012 in Japan. The agent inhibits the production of immunoglobulins and various inflammatory cytokines (interleukin-1, -6 and -8 and TNF), and exerts anabolic effects on bone metabolism by stimulating osteoblastic differentiation and inhibiting osteoclastogenesis in mice through inhibiting the nuclear transcription factor NF-κB, but not its inhibitor, IκBα. In addition this agent is very cheap (1.5$/25 mg tablet) , so 50 mg/day iguratimod therapy costs only 3$/day. In this study, We evaluate the efficacy and safety of iguratimod for RA patients. In addition, We examine NK cell counts compared with tofacitinib to evaluate the mechanism of the safety.

Methods: 62 patients who were administered iguratimod at a dosage of 25mg qd during the first month, then 50mg qd thereafter, and followed up for 24 weeks were enrolled. Efficacy and safety were evaluated utilizing clinical and laboratory findings. We also monitor the NK cell counts in peripheral blood from 20 RA patients before and 12 weeks after the commencement of Iguratimod by flow cytometery analysis.

Results: The mean age was 61.6 years and 75.8% of patients were female. MTX was used in 46.8%, the average dose was 8.6±2.9 mg/week. LOCF analysis revealed that DAS28-ESR and SDAI decreased significantly from 4.49±1.33 to 3.09±1.12 and from 18.5±10.9 to 7.44±7.11 in 24 weeks respectively (P<0.01). Remission and LDA rate in SDAI were 30.4% and 47.8%.  HAQ-DI score also decreased from 1.2±0.8 to 0.94±0.85.The difference between the efficacy of igurarimod with and without MTX was not significant. 29.0% of the patients discontinued iguratimod within 24 weeks. The reason of cessation consisted of adverse events (21.0%) and lack of efficacy (4.8%). Adverse events were digestive symptom (n=6), liver dysfunction (n=3), nasal hemorrhage (n=2) and so on. There’s no severe adverse event. Peripheral NK cell counts in 12 weeks had not been changed significantly. 

Conclusion: Iguratimod was well tolerable and may have a good cost effectiveness. So iguratimod be a new useful option as small molecule DMARDs for RA patients in a manner similar to tofacitinib.


Disclosure:

T. Kondo,
None;

A. Shibata,
None;

R. Sakai,
None;

K. Chino,
None;

A. Okuyama,
None;

H. Takei,
None;

K. Amano,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-iguratimod-for-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology